Cannabis and its Derivatives: Guide to Medical Application and Regulatory Challenges summarizes the current state of research and clinical pharmacology of cannabis-based therapeutics, along with associated regulatory frameworks. Sections cover historical, botanical, and taxonomical platforms of cannabis, chemical derivatives of the cannabis plant, a literature review of therapeutic applications, the biological fate of cannabis and its metabolic products, pain management, neurological disorders, cancer management, interactions with other drugs, veterinary applications, and the adverse effects of Cannabis overuse in humans. The book's final section is devoted to discussions around regulatory challenges and future considerations. This is the ideal reference pharmaceutical scientists, clinicians, and academic researchers who want access to updated information on the therapeutic applications of cannabis and its derivates. Corporate researchers will also benefit from this book's presentation of the associated regulatory environment.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Part I
Introduction 1. Historical, botanical, and taxonomical platform of Cannabis 2. Chemical derivatives of Cannabis plant 3. Therapeutic application of Cannabis and its derivatives: A detailed literature review about mechanisms of action 4. Biological fate of Cannabis and its metabolic products
Part II
Therapeutic potential 5. Cannabis therapeutic application in neurological disorder 6. Potential of Cannabis in pain management 7. Cannabis as drug of abuse and banned 8. Application of Cannabis in cancer management therapy 9. Cannabis interaction with other drugs 10. Cannabis in veterinary medicine
Part III
Regulatory aspects 11. Regulatory challenges on Cannabis: Concern, advantages, and disadvantages 12. Clinical application and future consideration and potential of Cannabis
Authors
Rahul Shukla Assistant Professor, Department of Pharmeceutics, National Institute of Pharmaceutical Education and Research, Raebareli, Uttar Pradesh, India.
Dr. Rahul Shukla is currently working as an Assistant Professor (Contract) at Department of Pharmaceutics, NIPER Raebareli, India, He has a PhD in Pharmaceutical Sciences from CSIR CDRI and J.N.U New Delhi, India, an M.Pharm from IIT BHU,Varanasi, India and B.Pharm from Jamia Hamdard, New Delhi. He has more than ten years of research and academic experience with more than 30 publications and 10 book chapters to his credit. He has filed 7 Indian Patent and 1 Copyright. Recently he has edited a book on the Role of Novel Drug Delivery Vehicles in Nanobiomedicine. His current research interests include?targeted drug delivery systems, particle?engineering, controlled delivery?for neurodegenerative diseases,?dendrimer mediated drug delivery, solubilization and bioavailability enhancements.
Mayank Handa National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, India.
Mr. Mayank Handa, has completed his B. Pharm and M. Pharm from U.I.P.S, Panjab University, Chandigarh India. Currently, pursuing as Ph.D. at National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow UP. His past industrial experience includes working at Eisai India Limited, India and Themis Medicare Limited, India. He has more than 20 peer reviewed publications in journals international repute and 10 book chapter. He has filed 5 Indian patent and 1 Copyright. His research interests in polymeric nanoparticles and emulsion based drug delivery, targeted drug delivery systems, Intranasal and transdermal drug delivery.
Dhirendra Pratap Singh Neurotoxicology and Immunotoxicology Laboratory, ICMR-National Institute of Occupational Health, Ahmedabad, India.
Dhirendra Pratap Singh is a trained pharmacologist, having special interest in behavioral neuropharmacology and gut microbial ecology for advanced understanding on gut-microbial-brain axis. He received his Ph.D. in Pharmaceutical Sciences from Panjab University, Chandigarh. He is currently working as Scientist 'C' in Neurotoxicology and Immunotoxicology laboratory at ICMR-National Institute of Occupational Health, Ahmedabad. Utilizing his expertise and skill in the interdisciplinary domains of chemical and life sciences he is leading a small independent research group. Two major domains of his research are, translational research for rapid and affordable diagnostics development for environmental toxicants exposure identifications, and basic research on studies exploring the gut microbial modulation strategies for improved brain functions. He has 25 research publication and 3 book chapters in the area of nutrition & metabolism, applied microbiology, neuropharmacology and currently in biomedical microdevices developments.
Ashish Dhir Associate Principal Scientist- Drug Discovery, USA.
Dr. Ashish Dhir is an Associate Principal Scientist in Drug Discovery for Merck in New Jersey. He was previously a Senior Scientist in the Department of Neurology, School of Medicine, University of California, Davis in Sacramento. He received his doctorate in Pharmacology from Panjab University, Chandigarh, India. He has over 15 years of experience in preclinical research in the field of neurological and neuropsychiatric disorders. Dr. Dhir's research entails establishing and validating animal models of various disease conditions, as well as investigating novel drugs and targets for disease treatment. Dr. Dhir has over 90 peer-reviewed journal papers and serves as an ad hoc reviewer and on the Editorial Board of several prestigious journals.?He was recently named to the list of the world's top 2% pharmacology scientists (ranking 1053 out of 94611). Dr. Dhir has received numerous honors, including the Rafaelsen Young Investigator Award from the Collegium International Neuropsychopharmacologicum (CINP).
